Psilocybin and the 5-HT2A Receptor Explained

Psilocybin Pharmacology

~72% peak 5-HT2A receptor occupancy in the human brain (dose-dependent)

PET imaging in humans showed psilocybin occupies 5-HT2A serotonin receptors in a dose-dependent way — reaching about 72% at higher doses — and that occupancy tracks the intensity of the psychedelic experience, the strongest direct human evidence that this receptor is the key mechanism.

Madsen et al., Neuropsychopharmacology, 2019

~72%

peak 5-HT2A receptor occupancy in humans, dose-dependent (Madsen 2019)

Golgi

site of the intracellular 5-HT2A receptors that drive brain plasticity (Vargas 2023)

Blocked

a selective 5-HT2A antagonist abolishes psychedelic-like effects, proving 5-HT2A primacy

Madsen et al., Neuropsychopharmacology, 2019

View as image ↗

SSRIs — the most widely prescribed antidepressants — target serotonin too. They flood the synapse with it by blocking its reabsorption. But SSRIs don't cause psychedelic experiences. They don't produce the rapid, lasting neuroplasticity seen after a single psilocybin session. For decades, this difference was treated as a dose or receptor subtype question. A 2023 paper in Science proposed a more fundamental explanation: psilocybin reaches receptors inside the cell that serotonin never can.

Understanding how psilocybin works through the psilocybin 5-HT2A receptor explains both the psychedelic experience and the therapeutic mechanism — and why the most intriguing findings of the past five years point to something more subtle than simple serotonin receptor activation. The full pharmacology arc — from how psilocybin converts to its active form through to how brain networks respond — is covered in the psilocybin pharmacology overview.

The Proof: Blocking 5-HT2A Eliminates the Psychedelic Experience

Before explaining what 5-HT2A receptors do, it's worth establishing that they are actually required. The cleanest evidence comes from pharmacological blocking experiments.

Erkizia-Santamaría and colleagues (2022) administered psilocybin to mice and measured the characteristic behavioral response — head-twitch, which is the standard animal proxy for psychedelic-like activity in humans.^[1] Then they pre-treated animals with MDL11939, a drug that selectively blocks the 5-HT2A receptor (the specific type of serotonin receptor psilocybin primarily targets). The head-twitch response was completely suppressed. (Ketanserin, another selective 5-HT2A antagonist, is used the same way to block psilocybin's effects in human studies.)

The same experiments tested whether 5-HT1A receptors or 5-HT2C receptors contributed to the psychedelic response. Neither played a role. Blocking 5-HT1A changed body temperature and anxiety-like behaviors but not the psychedelic response. Blocking 5-HT2C similarly affected thermoregulation but left the psychedelic response intact.

The conclusion is unusually clean: the 5-HT2A receptor is not just important — it is necessary. Without it, psilocybin produces no psychedelic effect, even when all other serotonin receptors are free to respond.

Nichols (2016), in a comprehensive 91-page review of serotonergic psychedelics in Pharmacological Reviews, established this same conclusion from the entire body of preclinical evidence: partial agonism at 5-HT2A is the defining pharmacological action of classic psychedelics as a class.^[9]

How Much of the Receptor Psilocybin Occupies: The PET Evidence

Animal experiments tell us the receptor is required. A 2019 clinical study told us how much of it gets occupied across a range of doses.

Madsen and colleagues (2019) gave eight healthy volunteers single oral doses of psilocybin spanning 3 to 30 mg and measured 5-HT2A receptor occupancy using PET brain imaging.^[2] PET can detect how much of a given receptor type is occupied by a drug at a given moment, because the radiotracer used to image the receptors competes with the drug for the same binding sites.

Occupancy rose with dose, reaching about 72% at the higher end. The intensity of the subjective psychedelic experience was correlated with both 5-HT2A occupancy and plasma levels of psilocin — more receptors occupied corresponded to a more intense experience.

Several things this tells us: even at the highest dose tested, psilocybin does not occupy all available receptors. Higher occupancy corresponds to a more intense experience. And the dose-experience relationship is driven by actual receptor pharmacology, not placebo or expectancy alone.

The Paradox: Fewer Receptors at Baseline Predicts a Stronger Experience

If receptor occupancy correlates with intensity, you might expect people with more receptors to have stronger experiences — more available binding sites, more total receptor activation. Stenbæk and colleagues (2021) tested this assumption in humans and found the opposite.^[3]

In sixteen healthy participants, the team used PET imaging to measure baseline 5-HT2A receptor binding before any psilocybin administration, then gave a single oral dose of 0.2–0.3 mg/kg and measured subjective effects. Stenbæk found that lower baseline 5-HT2A binding in the neocortex predicted stronger mystical experience intensity (a significant negative association with Mystical Experience Questionnaire scores).

The explanation is not fully settled, but one leading interpretation involves receptor sensitivity rather than receptor count: fewer receptors may mean the downstream signaling pathway is less subject to desensitization, so each receptor that does get activated produces a stronger downstream effect. The brain's signaling systems are not simply proportional — receptor count is one variable, but the sensitivity of the circuits downstream of those receptors matters as much as the count.

This finding has practical implications for understanding why psilocybin responses vary so dramatically between individuals. Prior antidepressant use (especially SSRIs) tends to reduce 5-HT2A receptor density through chronic exposure — which may partly explain why people taking SSRIs often report blunted psychedelic responses.

The 2023 Discovery: Why Serotonin Doesn't Cause the Same Plasticity

The most significant mechanistic finding in psilocybin pharmacology in recent years came from Vargas and colleagues (2023), published in Science: psychedelics produce neuroplasticity by activating 5-HT2A receptors inside the cell — specifically in the Golgi apparatus, which is the cell's internal processing and sorting station.^[4]

The distinction between surface and intracellular matters because serotonin cannot cross the cell membrane. It is water-soluble and gets released into the synaptic cleft, where it binds to receptors on the cell surface. Those surface receptors trigger acute signaling — they affect immediate neural activity. But serotonin never reaches the Golgi.

Psilocin (the active form of psilocybin) is lipid-soluble. It passes through the cell membrane freely and accumulates inside the neuron, where it reaches 5-HT2A receptors sitting on the Golgi apparatus. Vargas and colleagues found that these intracellular receptors, when activated, trigger a specific signaling cascade — through mTOR, a cellular growth regulator, and downstream pathways — that causes dendritic spine growth. Dendritic spines are tiny branch-like protrusions on neurons that are the physical substrate of new synaptic connections.

This explains the fundamental puzzle: serotonin and psilocybin both activate 5-HT2A receptors. But only psilocybin — and other lipid-soluble psychedelics — trigger neuroplasticity. The difference is that serotonin only reaches surface receptors, while psilocybin reaches both surface and intracellular receptors. The neuroplasticity comes from the intracellular ones.

For people who have wondered why SSRIs, which increase serotonin signaling extensively, don't produce anything like psilocybin's rapid and lasting antidepressant effects — this is the mechanistic explanation. The receptors involved are different, even though they share the same protein name.

Shao and colleagues (2024, preprint, not yet peer-reviewed) extended this story to a specific cell type: in the mouse medial frontal cortex, a particular class of pyramidal neurons — the subcortically-projecting "pyramidal tract" cells — appears to be the critical population for psilocybin's lasting drug action.^[5] A single dose grew dendritic spines on both major pyramidal cell types, but silencing the pyramidal-tract neurons abolished psilocybin's ability to relieve stress-related behavior, while silencing the other type had no detectable effect. Knocking out the 5-HT2A receptor entirely abolished both the behavioral benefit and the structural plasticity. Because this is a preprint, the finding should be treated as preliminary until peer review.

What Happens to 5-HT2A Density After a Session

If psilocybin activates 5-HT2A receptors intensely in a single session, what happens to receptor density afterward? Raval and colleagues (2021) answered this directly in pig brains, which are anatomically similar to human brains in ways relevant to neuroimaging.^[6] Twenty-four pigs received a single intravenous dose of psilocybin or saline; the researchers then measured synaptic density (using the SV2A marker) and 5-HT2A receptor density in brain tissue at one day and at seven days.

The two effects ran on different timelines:

• Receptor density (acute): one day after dosing, 5-HT2A receptor density was reduced in the hippocampus and prefrontal cortex (the brain appeared to downregulate the receptor). By seven days, this difference had resolved — receptor density was no longer significantly different from controls.
• Synaptic density (persistent): synaptic (SV2A) density was higher seven days after a single dose — by roughly 9% in the hippocampus and 6% in the prefrontal cortex.

The acute receptor downregulation is a standard homeostatic response: when a receptor is heavily stimulated, the cell typically reduces the number of surface receptors as a compensatory adjustment. This same process underlies tolerance — which is why repeat psilocybin administration in rapid succession produces diminishing effects.

The lasting synaptic-density increase is the neuroplasticity effect. More synaptic terminals at seven days represents new connections formed in response to the psilocybin session — and unlike the receptor change, it persists. This is the cellular substrate of the lasting therapeutic effects observed in clinical trials.

The pattern — a transient dip in surface receptors followed by a durable gain in synapses — fits the Vargas 2023 framework: the surface receptors get downregulated and then recover, but the intracellular receptor activity has already triggered the plasticity cascade that builds new connections that outlast the acute pharmacology.

The Other Serotonin Receptors: What They Actually Do

The 5-HT1A and 5-HT2C receptors that the Erkizia-Santamaría experiments ruled out as responsible for psychedelic effects are not irrelevant — they just do different things.^[1]

5-HT1A activation causes anxiolysis (reduced anxiety) and hypothermia at high doses. In psilocybin sessions, the calming and physically grounding aspects of the experience may partly involve 5-HT1A. Nichols (2016) notes that psilocin binds 5-HT1A with lower affinity than 5-HT2A — it's a secondary binding site, not the primary one.^[9]

5-HT2C modulates feeding behavior, anxiety, and thermoregulation. It shares structural similarity with 5-HT2A and is activated by psilocin, but the downstream signaling is distinct and doesn't produce psychedelic effects.

McClure-Begley and Roth (2022), in a Nature Reviews Drug Discovery analysis of psychedelic pharmacology, introduced the concept of biased agonism as a potential future direction: the 5-HT2A receptor can trigger different downstream pathways depending on which part of its molecular structure is engaged.^[10] Gq signaling (one downstream pathway) appears to produce the acute psychedelic effects. Beta-arrestin2 signaling (another pathway) appears to be more involved in neuroplasticity. A molecule that selectively activates only the beta-arrestin2 pathway might produce the brain changes — potentially including antidepressant effects — without the subjective psychedelic experience. Such molecules are called psychoplastogens, and several research groups are actively developing them.

Beyond Serotonin: Microglial Pathways

Two recent studies have identified a 5-HT2A-independent mechanism for psilocybin's effects on brain cells — specifically the brain's immune cells (microglia).

Wiens and colleagues (2024) found that psilocin reduces the production of inflammatory proteins by microglia — specifically TNF-alpha and IL-6, two key mediators of neuroinflammation — in a way that requires 5-HT2 receptors.^[7] This suggests psilocybin has an anti-inflammatory component on top of its neuroplasticity effects.

Laabi and colleagues (2025) extended this further: both psilocybin and psilocin regulate microglial activity through two separate pathways — the serotonin 5-HT2A pathway, and a completely separate immune signaling pathway called the aryl hydrocarbon receptor (AhR) pathway.^[8] AhR is involved in regulating immune responses to environmental signals. The existence of a non-serotonergic mechanism means some of psilocybin's effects on brain inflammation may not be blocked by ketanserin — adding complexity to the simple "5-HT2A explains everything" picture.

Both studies are preclinical and in-vitro. Whether the microglial anti-inflammatory effects translate to clinically meaningful outcomes in humans is not yet established. They add mechanistic breadth to the psilocybin pharmacology story rather than clinically actionable findings.

The Bottom Line

The 5-HT2A serotonin receptor is the required target for psilocybin's psychedelic effects — blocking it eliminates the experience entirely. Clinical PET data quantifies the dose-occupancy relationship (dose-dependent occupancy reaching about 72% in humans) and the surprising inverse relationship between baseline receptor density and experience intensity. The 2023 Vargas Science paper fundamentally changed the mechanistic picture: the neuroplasticity-driving action happens at intracellular 5-HT2A receptors inside neurons, which serotonin cannot reach — explaining why SSRIs don't produce similar effects. Emerging research shows psilocin also acts on microglial immune cells through a parallel non-serotonergic pathway.

Frequently Asked Questions

Why does psilocybin affect serotonin receptors?

Psilocin (the active form of psilocybin) has a molecular shape that fits into the 5-HT2A serotonin receptor — the same receptor that serotonin itself uses. Psilocin acts as a partial agonist, meaning it activates the receptor but less completely than serotonin. This serotonin receptor activation is the initiating event for both the psychedelic experience and the downstream neuroplasticity effects.

Does blocking the 5-HT2A receptor stop the psilocybin experience?

Yes. Erkizia-Santamaría et al. (2022) found that pre-treating with MDL11939 — a drug that selectively blocks the 5-HT2A receptor — completely suppressed the psychedelic-like (head-twitch) response to psilocybin in mice. No other serotonin receptor could compensate. Human studies use ketanserin, another selective 5-HT2A antagonist, the same way. This confirms 5-HT2A is not just important but necessary for psychedelic effects.

What is the difference between 5-HT1A and 5-HT2A receptors?

Both are serotonin receptor types, but they trigger different effects. 5-HT2A is responsible for psychedelic effects, hallucinations, and the neuroplasticity that follows. 5-HT1A produces anxiolysis and thermoregulatory effects but not psychedelic responses. Psilocin binds both, but with higher affinity for 5-HT2A — which is why the psychedelic effect dominates.

Why is ketanserin used to block psilocybin?

Ketanserin selectively blocks 5-HT2A receptors, which makes it a precise research tool for testing whether 5-HT2A is required for a given psilocybin effect. If ketanserin eliminates an effect, that effect is 5-HT2A-dependent. If an effect persists, it involves other receptors. This approach confirmed that the psychedelic response requires 5-HT2A while some other physiological effects (temperature, anxiety) do not.

What percentage of 5-HT2A receptors does psilocybin occupy?

It depends on the dose. PET imaging in humans found that occupancy rises with dose, reaching about 72% at the higher end of the range tested (single oral doses of 3–30 mg; Madsen et al., 2019). The intensity of the subjective experience tracked both occupancy and plasma psilocin levels — the more receptors occupied, the more intense the experience. Even at the highest dose tested, some receptors remained unoccupied.

Sources & References

1. 1RTHM-00757·Erkizia-Santamaría, I et al. (2022). “Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response..” Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.Study breakdown →PubMed →↩
2. 2RTHM-00578·Madsen, Martin K et al. (2019). “Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels..” Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.Study breakdown →PubMed →↩
3. 3RTHM-00720·Stenbæk, Dea Siggaard et al. (2021). “Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans..” Journal of psychopharmacology (Oxford.Study breakdown →PubMed →↩
4. 4RTHM-01813·Vargas, Maxemiliano V et al. (2023). “Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors..” Science (New York.Study breakdown →PubMed →↩
5. 5RTHM-00906·Shao, Ling-Xiao et al. (2024). “Pyramidal cell types and 5-HT2A receptors are essential for psilocybin's lasting drug action..” bioRxiv : the preprint server for biology.Study breakdown →PubMed →↩
6. 6RTHM-00714·Raval, Nakul Ravi et al. (2021). “A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain..” International journal of molecular sciences.Study breakdown →PubMed →↩
7. 7RTHM-00914·Wiens, Kennedy R et al. (2024). “Psilocin, the Psychoactive Metabolite of Psilocybin, Modulates Select Neuroimmune Functions of Microglial Cells in a 5-HT2 Receptor-Dependent Manner..” Molecules (Basel.Study breakdown →PubMed →↩
8. 8RTHM-00934·Laabi, Salma et al. (2025). “Psilocybin and psilocin regulate microglial immunomodulation and support neuroplasticity via serotonergic and AhR signaling..” International immunopharmacology.Study breakdown →PubMed →↩
9. 9RTHM-00439·Nichols, David E (2016). “Psychedelics..” Pharmacological reviews.Study breakdown →PubMed →↩
10. 10RTHM-00787·McClure-Begley, Tristan D et al. (2022). “The promises and perils of psychedelic pharmacology for psychiatry..” Nature reviews. Drug discovery.Study breakdown →PubMed →↩